AVOI yields 307.69% · ABBV yields 3.06%● Live data
📍 AVOI pulled ahead of the other in Year 1
Combined, AVOI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AVOI + ABBV for your $10,000?
Advanced Voice Recognition Systems, Inc., a software development company, specializes in creating interface and application solutions for speech recognition technologies in the United States. Its principal proposed product or service includes speech recognition software and related firmware, which allows for dictation into a range of applications comprising DOS applications running in Windows; UNIX and mainframe applications accessed through terminal emulation programs; various custom applications; and Windows 3.x, 95, 98, 2000, XP, Vista, Windows 7, and Windows 10 programs. The company also focuses on offering AVRS Enterprise solutions that are applicable to various primary stream speech enabled applications, such as traditional desktop applications, as well as mobile and web-based, and cloud solutions. It focuses on serving corporations, hospitals, medical product and service providers, governmental entities, legal professionals, sales and service organizations, law enforcement agencies, and mobile search and voicemail to text markets that require individuals and organizations to create reports, letters, email, data entry, manuals, books, and other documents or end products involving written data. The company was founded in 1994 and is headquartered in Scottsdale, Arizona.
Full AVOI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.